Literature DB >> 2714735

Bile acid metabolism in human hyperthyroidism.

J Pauletzki1, F Stellaard, G Paumgartner.   

Abstract

Decreased levels of serum cholesterol are a well-recognized finding in hyperthyroidism. Since the conversion to bile acids is an important pathway for the elimination of cholesterol, we studied primary bile acid kinetics in seven hyperthyroid patients before and after medical treatment. Pool sizes, fractional turnover and synthesis rates of cholic acid and chenodeoxycholic acid were determined after oral administration of 50 mg [13C]cholic acid and 50 mg [13C]chenodeoxycholic acid. 13C/12C isotope ratios in serum were measured by capillary gas chromatography/electron impact mass spectrometry. Compared with the euthyroid state, serum cholesterol levels were distinctly lower in hyperthyroidism (150 +/- 33 vs. 261 +/- 51 mg per dl, p less than 0.01). Thyroid hormone excess caused a 34% reduction in cholic acid synthesis (5.8 +/- 2.8 vs. 7.9 +/- 4.2 mu moles per kg per day, p less than 0.02), which was associated with a 47% decrease in cholic acid pool size (11.7 +/- 3.4 vs. 22.0 +/- 5.2 mu moles per kg, p less than 0.01). Chenodeoxycholic acid kinetics exhibited no apparent changes. Thus, total primary bile acid synthesis was diminished by 20% in hyperthyroidism. After normalization of thyroid function, the ratio of cholic acid/chenodeoxycholic acid pool size increased in all patients. This was paralleled by a rise in the ratio of concentrations of cholic acid/chenodeoxycholic acid in serum. The depression of cholic acid synthesis in the presence of unaltered subjects is compatible with an inhibition of hepatic 12 alpha-hydroxylation by thyroid hormone. Furthermore, evidence is provided that, in man, the low serum cholesterol levels found during hyperthyroidism are not caused by an increased conversion of cholesterol to bile acid.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2714735     DOI: 10.1002/hep.1840090610

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

1.  Resolution of propylthiouracil-induced hepatic failure after treatment of thyrotoxicosis.

Authors:  W Khovidhunkit; R V Farese
Journal:  West J Med       Date:  1997-11

2.  A bioequivalence study of levothyroxine tablets versus an oral levothyroxine solution in healthy volunteers.

Authors:  N Yannovits; E Zintzaras; A Pouli; G Koukoulis; S Lyberi; E Savari; S Potamianos; F Triposkiadis; I Stefanidis; E Zartaloudis; A Benakis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2006 Apr-Jun       Impact factor: 2.441

3.  Suppression of bile acid synthesis by thyroid hormone in primary human hepatocytes.

Authors:  Ewa Cristine Siljevik Ellis
Journal:  World J Gastroenterol       Date:  2006-08-07       Impact factor: 5.742

4.  The Aging Features of Thyrotoxicosis Mice: Malnutrition, Immunosenescence and Lipotoxicity.

Authors:  Qin Feng; Wenkai Xia; Guoxin Dai; Jingang Lv; Jian Yang; Deshan Liu; Guimin Zhang
Journal:  Front Immunol       Date:  2022-06-02       Impact factor: 8.786

Review 5.  Hypothyroidism and dyslipidemia: modern concepts and approaches.

Authors:  Elizabeth N Pearce
Journal:  Curr Cardiol Rep       Date:  2004-11       Impact factor: 2.931

6.  High serum bile acids cause hyperthyroidism and goiter.

Authors:  Ken-Ichi Mukaisho; Yoshio Araki; Hiroyuki Sugihara; Hiroyuki Tanaka; Kuan-Hao Chen; Takanori Hattori
Journal:  Dig Dis Sci       Date:  2007-10-12       Impact factor: 3.199

Review 7.  The use of stable and radioactive sterol tracers as a tool to investigate cholesterol degradation to bile acids in humans in vivo.

Authors:  Marco Bertolotti; Andrea Crosignani; Marina Del Puppo
Journal:  Molecules       Date:  2012-02-16       Impact factor: 4.411

8.  Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans.

Authors:  Ylva Bonde; Olof Breuer; Dieter Lütjohann; Stefan Sjöberg; Bo Angelin; Mats Rudling
Journal:  J Lipid Res       Date:  2014-08-29       Impact factor: 5.922

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.